Weil was engaged by the Audit Committee of the Board of Directors of ARCP, a publicly-traded real estate investment trust, to conduct an internal investigation of allegations of accounting irregularities. The investigation resulted in a restatement and the separation from the company of several top executives. A multi-disciplinary Weil team advised the Audit Committee and the Board of Directors with respect to all aspects of the investigation and the resulting fallout.

Weil is representing a former senior trader at a major financial institution in connection with the U.S. Department of Justice’s criminal investigation into alleged manipulation of LIBOR – without question the DOJ’s highest profile ongoing investigation and one that to date has led to aggregate penalties exceeding $2 billion.

Weil serves as lead counsel overseeing the defense of Toyobo, a major Japanese fiber manufacturer, in connection with potential False Claims Act claims by the U.S. DOJ, class action suits, multiple personal injury suits, and claims by multiple state attorneys general and foreign states, among others, relating to the performance of Toyobo’s Zylon fiber in bullet-resistant vests used by thousands of law enforcement agencies worldwide.

Weil is coordinating investigations and litigation in the United States for a leading provider of benchmark price assessments for the crude-oil market, which has come under scrutiny by a European Commission probe of price-fixing in the $3.4 trillion market. The E.C. has been seeking evidence of price-fixing by three of Europe’s biggest oil explorers – Royal Dutch Shell, BP, and Statoil.

In the United States, the Federal Trade Commission and Commodity Futures Trading Commission have started an investigation into alleged price manipulation. Numerous private antitrust class action lawsuits have been filed in the United States against Shell, BP, and Statoil, although our client has not yet been named as a defendant in those lawsuits.

In this complex and sensitive cross-border matter, we have been coordinating our efforts with investigations and litigation in the European Union.

Weil represented AIG in connection with inquiries by federal, state and international agencies, including the U.S. Securities and Exchange Commission, the U.S. Department of Justice, multiple state attorney generals’ offices, the U.S. Office of the Special Inspector General for the Troubled Asset Relief Program, the U.K. Serious Fraud Office, the U.K. Financial Services Authority, as well as numerous inquiries by various Senate and House committees and congressionally-appointed commissions and panels, including the Financial Crisis Inquiry Commission and the Congressional Oversight Panel, arising out of AIG’s subprime related losses, AIG’s receipt of emergency funding by the federal government in late 2008, and compensation issues that have been the subject of much national media attention.

Weil is representing a number of major companies in a variety of sensitive regulatory investigations, including:

• An SEC investigation into a failed IPO of an electronic trading platform
• An SEC investigation and related class action litigation involving the underwriting of a SaaS provider
• A CFTC investigation into a conspiracy to manipulate the ISDAFix, the International Swaps and Derivatives Association’s benchmark rate for the swaps market

We are advising certain former executives of a major European distiller and liquor distributor with respect to DOJ and SEC investigations into alleged FCPA violations. We also represent the company in related U.S. securities fraud litigation.

We are advising a major enterprise software maker on the design and execution of a thorough FCPA due diligence plan following its $1.7 billion acquisition of a packet-technology company.

We are advising a global pharmaceutical company in wide-ranging investigations across multiple continents related to the FCPA and other issues.

Weil represents a major healthcare provider in connection with an investigation into alleged False Claims Act violations.